What is Enlivex Ltd's earnings per share (EPS)?

Enlivex Ltd (ENLV) reported diluted earnings per share of $25.48 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Enlivex Ltd Financials

ENLV

Source SEC Filings (10-K/10-Q) Updated Mar 25, 2026 Currency USD FYE March

This page shows Enlivex Ltd (ENLV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Enlivex Ltd passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

-0.01x

For every $1 of reported earnings, Enlivex Ltd generates $-0.01 in operating cash flow (-$10.4M OCF vs $1.2B net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$14.7M

YoY+4.2%

Enlivex Ltd's EBITDA was -$14.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.2% from the prior year.

Net Income

$1.2B

YoY+8329.2%

Enlivex Ltd reported $1.2B in net income in fiscal year 2025. This represents an increase of 8329.2% from the prior year.

EPS (Diluted)

$25.48

Enlivex Ltd earned $25.48 per diluted share (EPS) in fiscal year 2025. This represents an increase of 3590.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$10.5M

YoY+20.0%

Enlivex Ltd generated -$10.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 20.0% from the prior year.

Cash & Debt

$1.9M

YoY-42.6%

5Y CAGR-19.7%

10Y CAGR-12.6%

Enlivex Ltd held $1.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

237M

Enlivex Ltd had 237M shares outstanding in fiscal year 2025. This represents an increase of 903.7% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

63.8%

YoY+127.5pp

5Y CAGR+97.2pp

10Y CAGR+149.5pp

Enlivex Ltd's ROE was 63.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 127.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$9.2M

YoY-13.4%

5Y CAGR+8.6%

10Y CAGR+1.8%

Enlivex Ltd invested $9.2M in research and development in fiscal year 2025. This represents a decrease of 13.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$68K

YoY-34.0%

5Y CAGR-41.8%

10Y CAGR+3.5%

Enlivex Ltd invested $68K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 34.0% from the prior year.

ENLV Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.2M-13.4%	$10.6M-44.1%	$19.0M+1.7%	$18.7M+45.1%	$12.9M+111.6%	$6.1M
SG&A Expenses	$5.8M+18.0%	$4.9M-20.0%	$6.1M-13.6%	$7.1M+10.9%	$6.4M+73.2%	$3.7M
Operating Income	-$15.0M+5.4%	-$15.9M+45.9%	-$29.4M-13.9%	-$25.8M-33.7%	-$19.3M-97.1%	-$9.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$382.6M	N/A	N/A	N/A	N/A	N/A
Net Income	$1.2B+8329.2%	-$15.0M+48.3%	-$29.1M+6.4%	-$31.1M-114.7%	-$14.5M-22.4%	-$11.8M
EPS (Diluted)	$25.48	$-0.73+53.2%	$-1.56+7.7%	$-1.69-108.6%	$-0.81+10.0%	$-0.90

Metric	Q1'26	Q4'25	Q3'25	Q1'25	Q4'24	Q3'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.1M	N/A	N/A	$2.0M	N/A	N/A	$5.0M	N/A
SG&A Expenses	$937K	N/A	N/A	$987K	N/A	N/A	$1.6M	N/A
Operating Income	-$3.1M	N/A	N/A	-$3.0M	N/A	N/A	-$6.6M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.9M+45.9%	-$3.5M	N/A	-$3.1M+25.2%	-$4.1M	N/A	-$6.8M+5.9%	-$7.2M
EPS (Diluted)	$-0.08	N/A	N/A	$-0.16	N/A	N/A	$-0.37	N/A

ENLV Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.3B+8304.7%	$27.7M-24.8%	$36.8M-45.6%	$67.6M-28.9%	$95.1M+135.8%	$40.4M
Current Assets	$1.7B+6606.3%	$26.0M-23.0%	$33.8M-35.5%	$52.3M-39.5%	$86.4M+126.8%	$38.1M
Cash & Equivalents	$1.9M-42.6%	$3.3M+306.0%	$813K-98.4%	$49.9M+345.9%	$11.2M+97.5%	$5.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$392.1M+9466.9%	$4.1M-39.3%	$6.7M-37.5%	$10.8M+6.9%	$10.1M+107.5%	$4.9M
Current Liabilities	$9.0M+137.5%	$3.8M-37.3%	$6.1M-8.3%	$6.6M+40.0%	$4.7M+7.9%	$4.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.9B+8102.8%	$23.6M-21.6%	$30.1M-47.1%	$56.8M-33.2%	$85.0M+139.6%	$35.5M
Retained Earnings	$1.1B+972.0%	-$127.1M-13.4%	-$112.1M-35.0%	-$83.0M-59.8%	-$52.0M-38.6%	-$37.5M

Metric	Q1'26	Q4'25	Q3'25	Q1'25	Q4'24	Q3'24	Q1'24	Q4'23
Total Assets	$22.6M	N/A	$27.7M-13.2%	$31.9M	N/A	$36.8M-30.5%	$53.0M	N/A
Current Assets	$21.3M	N/A	$26.0M-9.0%	$28.6M	N/A	$33.8M+9.7%	$30.8M	N/A
Cash & Equivalents	$1.9M	N/A	$3.3M-11.9%	$3.7M	N/A	$813K-76.5%	$3.5M	N/A
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.5M	N/A	$4.1M+22.7%	$3.3M	N/A	$6.7M-22.4%	$8.7M	N/A
Current Liabilities	$3.3M	N/A	$3.8M+33.7%	$2.8M	N/A	$6.1M+21.4%	$5.0M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$7.2M	N/A
Total Equity	$19.1M-7.6%	$20.6M-12.6%	$23.6M-17.4%	$28.6M+6.4%	$26.9M-10.7%	$30.1M-32.1%	$44.3M-12.3%	$50.6M
Retained Earnings	-$132.4M	N/A	-$127.1M-6.5%	-$119.3M	N/A	-$112.1M-15.5%	-$97.0M	N/A

ENLV Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$10.4M+19.9%	-$13.0M+44.7%	-$23.5M+1.8%	-$24.0M-36.5%	-$17.5M-59.4%	-$11.0M
Capital Expenditures	$68K-34.0%	$103K-56.4%	$236K-97.1%	$8.1M+399.8%	$1.6M+59.5%	$1.0M
Free Cash Flow	-$10.5M+20.0%	-$13.1M+44.8%	-$23.8M+25.9%	-$32.1M-67.3%	-$19.2M-59.4%	-$12.0M
Investing Cash Flow	-$1.3M-114.6%	$9.1M+134.9%	-$26.0M-141.5%	$62.5M+262.8%	-$38.4M-83.1%	-$21.0M
Financing Cash Flow	$10.4M+60.8%	$6.5M+1692.8%	$360K+140.0%	$150K-99.8%	$61.0M+84.3%	$33.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q1'25	Q4'24	Q3'24	Q1'24	Q4'23
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ENLV Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	63.8%+127.5pp	-63.6%+33.0pp	-96.6%-42.0pp	-54.6%-37.6pp	-17.0%+16.3pp	-33.3%
Return on Assets	53.1%+107.3pp	-54.2%+24.7pp	-78.9%-33.0pp	-45.9%-30.7pp	-15.2%+14.1pp	-29.3%
Current Ratio	193.24+186.4	6.84+1.3	5.57-2.3	7.92-10.4	18.32+9.6	8.72
Debt-to-Equity	0.20+0.0	0.17-0.1	0.22+0.0	0.19+0.1	0.12-0.0	0.14
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q1'25	Q4'24	Q3'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-9.8%+6.9pp	-16.7%	N/A	-10.8%+4.6pp	-15.4%	N/A	-15.3%-1.1pp	-14.3%
Return on Assets	-8.3%	N/A	N/A	-9.7%	N/A	N/A	-12.8%	N/A
Current Ratio	6.41	N/A	6.84-3.2	10.06	N/A	5.57-0.6	6.17	N/A
Debt-to-Equity	0.19	N/A	0.17+0.1	0.12	N/A	0.22+0.1	0.16	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Akari Therapeutics Plc AKTX

$5.1M

SeaStar Medical Holding Corp ICU

$17.2M

Tenax Therapeutics Inc TENX

$258.2M

Rein Therapeutics, Inc. RNTX

$33.9M

Q32 BIO INC QTTB

$93.3M

Frequently Asked Questions

Is Enlivex Ltd profitable?

Yes, Enlivex Ltd (ENLV) reported a net income of $1.2B in fiscal year 2025.

What is Enlivex Ltd's EBITDA?

Enlivex Ltd (ENLV) had EBITDA of -$14.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Enlivex Ltd's return on equity (ROE)?

Enlivex Ltd (ENLV) has a return on equity of 63.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Enlivex Ltd's free cash flow?

Enlivex Ltd (ENLV) generated -$10.5M in free cash flow during fiscal year 2025. This represents a 20.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Enlivex Ltd's operating cash flow?

Enlivex Ltd (ENLV) generated -$10.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Enlivex Ltd's total assets?

Enlivex Ltd (ENLV) had $2.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Enlivex Ltd's capital expenditures?

Enlivex Ltd (ENLV) invested $68K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Enlivex Ltd spend on research and development?

Enlivex Ltd (ENLV) invested $9.2M in research and development during fiscal year 2025.

How many shares does Enlivex Ltd have outstanding?

Enlivex Ltd (ENLV) had 237M shares outstanding as of fiscal year 2025.

What is Enlivex Ltd's current ratio?

Enlivex Ltd (ENLV) had a current ratio of 193.24 as of fiscal year 2025, which is generally considered healthy.

What is Enlivex Ltd's debt-to-equity ratio?

Enlivex Ltd (ENLV) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Enlivex Ltd's return on assets (ROA)?

Enlivex Ltd (ENLV) had a return on assets of 53.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Enlivex Ltd's cash runway?

Based on fiscal year 2025 data, Enlivex Ltd (ENLV) had $1.9M in cash against an annual operating cash burn of $10.4M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Enlivex Ltd's Piotroski F-Score?

Enlivex Ltd (ENLV) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Enlivex Ltd's earnings high quality?

Enlivex Ltd (ENLV) has an earnings quality ratio of -0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.